Research

Mounjaro and heart health: cardiovascular and metabolic advances

Tirzepatide has gained approval to reduce cardiovascular risk in high-risk type 2 diabetes. Recent research also confirms its efficacy in early use and its action on energy metabolism.

Last updated: September 2026

Cardiovascular protection: the SURPASS-CVOT study

Mounjaro (tirzepatide) has received regulatory approval to reduce the risk of major adverse cardiovascular events — heart attacks, non-fatal strokes and cardiovascular death — in adults with high-risk type 2 diabetes. The evidence comes from the large-scale SURPASS-CVOT trial, one of the biggest cardiovascular outcomes studies ever conducted with a GIP/GLP-1 agonist.

Key findings:

8% reduction in the rate of major adverse cardiovascular events (MACE: myocardial infarction, non-fatal stroke or cardiovascular death) compared to placebo.
Sustained benefit throughout the study, consistent across subgroups of age, sex and BMI.
Safety profile consistent with previous tirzepatide trials: no new risk signals.

This result places tirzepatide alongside semaglutide (SELECT trial, 2024) as one of the GLP-1s with demonstrated cardiometabolic protection in large-scale trials.

Early use in type 2 diabetes

Recent research confirms that administering tirzepatide in the early stages of type 2 diabetes — when pancreatic function is still partially preserved — can produce especially powerful results:

Over 60% of patients achieved normal blood sugar levels (HbA1c below 5.7%, considered the non-diabetic range).
Response was greater in patients with shorter diabetes duration, suggesting that early intervention takes advantage of a window of greater metabolic reversibility.
Beyond blood sugar normalisation, improvements in triglycerides, blood pressure and inflammatory markers were also observed.

These data reinforce the clinical trend towards more aggressive treatment from diagnosis, rather than the traditional gradual escalation.

Brown fat activation and energy expenditure

One of the most interesting findings from recent tirzepatide research goes beyond simple appetite suppression. Preclinical and translational studies show that the drug:

Stimulates brown fat (brown adipose tissue), a metabolically active type of fat that burns calories to generate heat.
Increases basal energy expenditure, meaning the body uses more energy at rest.
Promotes "browning" — the conversion of white fat (storage) into beige fat (with thermogenic capacity).

This dual mechanism — lower calorie intake through satiety + higher energy expenditure — may explain why tirzepatide achieves greater weight loss than other GLP-1s that act on appetite alone.

Established benefits of Mounjaro

Beyond these new findings, accumulated evidence confirms the well-known benefits of tirzepatide:

Sustained weight loss: 15% to 22% of total body weight in the SURMOUNT trials, among the largest reductions recorded with pharmacotherapy.
Dual hormonal action: tirzepatide acts simultaneously on GIP and GLP-1 receptors. This combination prolongs satiety, improves insulin secretion and may have additional protective effects on bone and lipid metabolism.
Visceral fat reduction: notable decrease in liver fat (hepatic steatosis) and abdominal fat volume, the most dangerous from a cardiometabolic standpoint.

What does this mean for patients?

The cardiovascular approval expands Mounjaro's profile from a weight and diabetes medication to a tool with documented cardiometabolic benefits. For patients with type 2 diabetes and elevated cardiovascular risk, it provides an additional reason to discuss treatment with their doctor.

The brown fat and early-use findings, while promising, are more recent and will need confirmation in longer-term trials. The science moves forward; these pages will be updated as new data are published.

Important: This information is educational and does not replace your doctor's advice. Mounjaro is a prescription medication. Treatment decisions — starting, dosing, changes — are made by your healthcare provider together with you.

Related guides

How to use your GLP-1 pen correctly — injection, sites, storage and common mistakes.
Nausea: what's normal and when to consult — the most common side effect and how to manage it.
What to eat during GLP-1 treatment — gentle foods, plate structure and nutritional gaps.
8 GLP-1 myths — what the science says vs. the most common claims.

Sources: SURPASS-CVOT study (Lilly, 2025–2026); SELECT trial — semaglutide cardiovascular (NEJM 2024); SURMOUNT-1 to 4 trials (tirzepatide in obesity); FDA prescribing information for Mounjaro (tirzepatide, 2022, 2026 update); tirzepatide and brown adipose tissue review (PMC 2025); ADA/EASD standards for early type 2 diabetes management (2024).